OPEN ACCESS

ISSN: 2835-9496

Nadora D, et al. (2025): 805
Ameri J Clin Med Re, 2025; 5(1): 100182
DOI: 10.71010/AJCMR.2025-e182

Research Article

American Journal of Clinical and Medical Research

Ethical Considerations for Dermatologists to Prescribe Emergency Contraceptives with Isotretinoin

Dawnica Nadora, MS, BS[1], Grace Herrick, BA[2], Nina Schur, MMS[3], Caroline Hunter, MPS[4], Kelly Frasier, DO, MS[5*], Lena Cole Speir, BS[6], Erin Pomerantz, BS[7], Emily Beer, BA[8]

[1]California Northstate University College of Medicine, Elk Grove, CA
[2]Alabama College of Osteopathic Medicine, Dothan, AL
[3]Lake Erie College of Osteopathic Medicine, Bradenton, FL
[4]Edward Via College of Osteopathic Medicine, Auburn, AL
[5]Department of Dermatology, Northwell Health, New Hyde Park, NY
[6]Edward Via College of Osteopathic Medicine, Auburn, AL
[7]Temple University Lewis Katz School of Medicine, Philadelphia, PA
[8]University of Lethbridge, Lethbridge, AB, Canada

Abstract

The use of isotretinoin, a common treatment for severe acne, presents significant ethical considerations surrounding the need for emergency contraceptive prescriptions by dermatologists. Isotretinoin is well-known for its teratogenic effects, leading to severe fetal malformations if taken during pregnancy. Consequently, patients receiving isotretinoin are typically enrolled in strict pregnancy prevention programs, commonly requiring two forms of birth control, emphasizing the need for effective contraception. While dermatologists play a critical role in managing acne and overseeing isotretinoin therapy, there remains an ethical question of their role and responsibility to ensure comprehensive patient care extends to reproductive health. Prescribing ECs alongside isotretinoin may serve not only as a precautionary measure for unintended pregnancies but also as an ethical obligation to provide holistic healthcare. Studies indicate that patients may experience barriers to accessing ECs, including stigma and misinformation, particularly in dermatology settings. By integrating EC prescriptions into isotretinoin therapy, dermatologists can mitigate the risks associated with unintended pregnancies while fostering an environment of trust and support. This approach emphasizes the importance of interdisciplinary collaboration amongst healthcare providers, reinforcing that dermatologists can and should strongly consider addressing broader health concerns, including reproductive health, to optimize patient outcomes. Advocating for the ethical inclusion of emergency contraceptive prescriptions in the isotretinoin treatment regimen reflects a commitment to patient-centered care, empowering individuals with the necessary resources to make informed decisions about their reproductive health while managing the complexities of severe acne treatment.

***Corresponding author:**

Kelly Frasier, DO, MS, Department of Dermatology, Northwell Health, New Hyde Park, NY. Email: kellymariefrasier@gmail.com

Citation: Nadora D, Herrick G, Schur N, Hunter C, Frasier K, et al. (2025) Ethical Considerations for Dermatologists to Prescribe Emergency Contraceptives with Isotretinoin. J Clin Med Re: AJCMR-182.

Received Date: 03 January, 2025; **Accepted Date:** 17 January, 2025; **Published Date:** 23 January, 2025

Introduction

Isotretinoin, a powerful retinoic acid derivative, has transformed the treatment landscape for moderate to severe acne, particularly for patients who have not responded to conventional therapies such as topical or oral antibiotics. While not fully understood, its mechanism involves reducing sebaceous gland activity and inhibiting keratinization, ultimately decreasing acne lesions and improving patient outcomes [1]. However, despite its effectiveness, isotretinoin is associated with significant risks, most notably its teratogenic potential [2]. Even minimal exposure to isotretinoin during pregnancy can result in severe congenital anomalies, including craniofacial, cardiac, central nervous system, and thymic defects, making pregnancy prevention an essential component of isotretinoin therapy [2].

To address these risks, regulatory frameworks such as the iPLEDGE program require stringent safeguards to minimize fetal exposure. These include the use of two forms of contraception, regular pregnancy testing, and strict adherence to prescribed guidelines. While iPLEDGE has successfully reduced instances of isotretinoin-related teratogenicity, it is not without limitations [3]. Adherence challenges, insufficient contraceptive education, and a lack of comprehensive patient support have highlighted gaps in existing protocol [4]. These shortcomings raise ethical questions about the dermatologist's responsibility to provide acne treatment and reproductive health guidance. In this context, the integration of emergency contraceptives (ECs) as part of isotretinoin therapy offers a critical opportunity to enhance patient care and mitigate unintended pregnancies.

Dermatologists play a pivotal role in managing isotretinoin therapy, addressing both the physical and psychological impacts of severe acne [5]. However, their role must also extend to addressing the burdens associated with strict contraceptive requirements, especially for patients who may be new to contraception. For many women, initiating isotretinoin therapy marks their first exposure to intensive contraceptive measures, making it vital for dermatologists to provide clear, accessible, and comprehensive information about all available options, including ECs [4]. This is particularly important given the barriers to accessing ECs, such as stigma, misinformation, and logistical challenges, which can leave patients vulnerable to unintended pregnancies despite their enrollment in pregnancy prevention programs.

Incorporating emergency contraceptive prescriptions into isotretinoin therapy aligns with the principles of beneficence and nonmaleficence by emphasizing patient safety and equipping individuals with the resources to make well-informed choices about their reproductive health [6]. Moreover, it reflects an interdisciplinary approach to patient care, emphasizing the importance of collaboration between dermatologists and reproductive health specialists to optimize outcomes. By examining the ethical implications of prescribing ECs alongside isotretinoin, this paper advocates for a patient-centered approach that reduces the risk of teratogenicity and fosters trust, autonomy, and comprehensive care in dermatologic practice.

Overview of Emergency Contraceptives

Emergency contraceptives are critical tools for preventing pregnancy after unprotected sexual intercourse or contraceptive failure. They include hormonal pills, such as levonorgestrel (LNG) and ulipristal acetate (UPA), and the copper intrauterine device (IUD) [7, 8]. These options differ in their mechanisms, timing, and accessibility. For example, LNG, commonly known as the "morning-after pill," delays or inhibits ovulation and is most effective when taken within 72 hours of intercourse [9]. In contrast, UPA, a selective progesterone receptor modulator, can be used up to five days after unprotected intercourse and demonstrates greater efficacy than LNG within that extended window [7]. The copper IUD, the most effective EC method with a success rate exceeding 99%, works by creating an inhospitable environment for sperm and ova, preventing fertilization [7].

Among these options, hormonal ECs such as LNG are widely accessible, and often available over the counter in many countries, making them a convenient choice for urgent needs. However, methods requiring medical intervention, such as UPA or copper IUD insertion, often face barriers, including limited availability and provider access. LNG and UPA are highly effective when taken promptly, although UPA provides superior efficacy in preventing pregnancy up to 120 hours post-intercourse [9, 8]. The copper IUD remains an ideal option for those seeking long-term contraception while simultaneously addressing emergency needs, though it is less commonly utilized due to its procedural requirements [7]. The role of EC in reproductive health is particularly crucial for individuals prescribed teratogenic medications like isotretinoin, where the consequences of pregnancy are severe. While the iPLEDGE program mandates the use of two contraceptive methods or strict abstinence, studies suggest that EC provides an additional safeguard against unplanned pregnancies [10]. It serves as a vital option for mitigating risks arising from contraceptive failure or unprotected intercourse [10]. This importance is further highlighted when considering the effectiveness of combining Tier 2 contraceptive options, such as oral contraceptives, with barrier methods like condoms to enhance pregnancy prevention.

Despite its potential benefits, EC is underutilized in dermatologic practice, often due to misconceptions about its safety, efficacy, and role in conjunction with isotretinoin therapy. Dermatologists prescribing isotretinoin can play a critical role in reducing unintended pregnancies by routinely discussing and offering EC as part of comprehensive patient care. Integrating EC into isotretinoin treatment plans not only reduces risks but also empowers patients with the knowledge and resources to protect their reproductive health effectively.

Understanding Isotretinoin and Teratogenicity

Approved by the US Food and Drug Administration (FDA) in 1982, isotretinoin is an oral medication commonly prescribed for severe, resistant, and nodular acne. It is also used off-label for moderate acne when conventional treatments, such as systemic antibiotics, have proven ineffective [11,12]. While the exact mechanism of isotretinoin remains unknown, its efficacy is attributed to its ability to reduce sebaceous gland size and suppress sebum production, resulting in decreased acne lesions and prevention of scarring [11,12]. Typically, isotretinoin therapy begins with a dose of 0.5 mg/kg/day and increases to 1.0 mg/kg/day as tolerated [12]. Lower starting doses may be required for some patients, but the drug demonstrates efficacy across dosing regimens, making it a cornerstone therapy for recalcitrant acne [12]. Its unparalleled success in treating severe acne underscores its importance in dermatologic care, but this benefit is tempered by the significant risks it carries for patients of childbearing potential.

Despite its therapeutic benefits, isotretinoin carries a well-documented and severe teratogenic risk. It is considered one of the most dangerous teratogens since thalidomide, with exposure during pregnancy leading to significant risks of fetal malformations [13]. The drug has been shown to affect multiple organ systems, including the brain, thymus, spinal cord, heart, ears, and craniofacial structures. Early studies reported that approximately 30% of isotretinoin-exposed pregnancies resulted in fetal malformations, with 30% of children experiencing mental deficits and up to 60% performing poorly on neuropsychological tests [13]. The teratogenic effects are believed to arise from isotretinoin's inhibitory action on neural crest cells, specifically through disruptions in cytosolic calcium and bleb formation that ultimately lead to cell death [13]. This extensive teratogenic profile highlights the absolute necessity of strict pregnancy prevention measures for any patient undergoing isotretinoin therapy.

The incidence of adverse pregnancy outcomes due to isotretinoin exposure is alarmingly high. A foundational study on retinoic acid embryopathy evaluated 154 pregnancies with isotretinoin exposure, finding 12 spontaneous abortions and 11 cases of fetal malformations [14]. In a subset of 36 prospectively observed pregnancies, there were 8 spontaneous abortions and 5 malformations [14]. Dai et al. have reported a malformation rate of 28% in prospectively observed pregnancies [15]. Such data provide a stark reminder of the consequences of isotretinoin-exposed pregnancies, underscoring the critical need for continued vigilance in pregnancy prevention strategies.

To reduce fetal exposure, the iPLEDGE program was introduced in 2006. This program requires registration of all clinicians, pharmacies, and distributors involved with isotretinoin and implements stringent protocols for prescribing the drug [16]. Female patients of childbearing potential must comply with strict measures, including the use of two forms of contraception, monthly pregnancy tests, and careful documentation of adherence to these requirements [16]. Despite its success in reducing fetal exposure, iPLEDGE has not eliminated isotretinoin-exposed pregnancies [17]. Following an initial decrease in pregnancy rates after the program's implementation, a plateau was observed around 2011, suggesting that other factors—such as increased contraceptive use beginning in the early 2000s—may have also contributed to the decline [17]. While iPLEDGE has undoubtedly improved

outcomes, these persistent gaps highlight the need for supplemental measures, such as integrating emergency contraception into isotretinoin care plans.

Isotretinoin's profound teratogenic effects demand comprehensive safeguards to prevent fetal exposure. Dermatologists prescribing isotretinoin have an ethical responsibility to educate patients about its risks and ensure robust pregnancy prevention measures are in place. Incorporating emergency contraception into isotretinoin therapy may serve as a critical adjunct to existing protocols, reducing the likelihood of unintended pregnancies and minimizing the devastating consequences of isotretinoin-related teratogenicity. Such an approach reflects a commitment to patient-centered care, emphasizing the importance of holistic strategies to optimize both dermatological and reproductive health outcomes.

Ethical Considerations in Dermatology

Dermatologists prescribing isotretinoin bear a critical responsibility to address the physical, psychological, and reproductive health needs of their patients. Severe acne can significantly impact mental health and social well-being, and isotretinoin therapy often provides life-changing relief [18]. However, the strict contraceptive requirements associated with this treatment can present additional burdens, particularly for patients of childbearing potential. Many women begin isotretinoin therapy without prior experience with contraception, making it essential for dermatologists to provide clear, comprehensive guidance about their options, including EC.

The initiation of isotretinoin therapy often requires patients to navigate complex and potentially overwhelming reproductive health protocols. Women enrolled in the iPLEDGE program, for instance, frequently report feeling alarmed or anxious about the strict warnings against pregnancy while on isotretinoin [19]. In some cases, this anxiety is exacerbated by inadequate counseling, which leaves patients unclear about their contraceptive choices or emergency options [19]. The requirement to use two simultaneous methods of contraception can also feel impractical and burdensome to some, leading to gaps in adherence [20]. Dermatologists have an ethical obligation to address these challenges by fostering open, judgment-free conversations about all available contraceptive methods, including EC. Clear and compassionate communication not only reduces patient stress but also strengthens trust, which is critical for adherence to treatment protocols.

Education about contraception, including emergency contraception, remains inadequate for many individuals, revealing critical gaps in reproductive health knowledge. For example, only 8% of women accurately assess the risk of conception from a single act of unprotected sex, while many overestimate the effectiveness of condoms and oral contraceptives or lack familiarity with intrauterine devices (IUDs) and EC [21]. Misinformation further exacerbates this issue, with common misconceptions about EC—such as beliefs that it causes infertility or is equivalent to abortion—leading to hesitation in its use when needed [22]. A case reported by Choi et al. highlights these gaps: a 29-year-old woman undergoing isotretinoin therapy for severe acne discontinued her oral contraceptive to pursue pregnancy but continued isotretinoin for two additional months [23]. Unaware of the teratogenic risks of isotretinoin, she became pregnant and later sought guidance from the Motherisk program in Canada. Upon learning of the severe fetal risks associated with isotretinoin exposure, she opted for termination [23]. This case emphasizes the urgent need for patient education about isotretinoin's teratogenic effects and the availability of EC as a preventive option in such situations. Dermatologists are uniquely positioned to bridge these knowledge gaps during isotretinoin consultations, providing patients with accurate, evidence-based contraceptive information.

Unfortunately, many dermatologists lack formal training in EC counseling. Only 7% of pediatric dermatologists report having received education on EC, and the same percentage includes EC as an option during initial isotretinoin visits [24]. This lack of training undermines the ability of dermatologists to fulfill their ethical obligation to prevent isotretinoin-exposed pregnancies. If dermatologists are unable to provide comprehensive contraceptive counseling, they must ensure their patients are referred to specialists who can. Additionally, the ethical principle of beneficence demands that dermatologists act in their patient's best interests, not only by managing their acne but also by addressing the broader health risks associated with treatment. Integrating discussions about EC into isotretinoin therapy aligns with this principle, empowering patients to make informed decisions about their reproductive health. By taking an active role in contraception counseling, dermatologists demonstrate a commitment to comprehensive, patient-centered care that respects autonomy and prioritizes safety.

Barriers to Accessing Emergency Contraceptives

Barriers to accessing emergency contraceptives are multifaceted, often rooted in societal stigma, misinformation, and limited awareness among both patients and healthcare providers. The stigma surrounding EC use is a significant obstacle, particularly in younger populations [25]. Kabunga et al. explored attitudes toward ECs among university students, finding that while many participants viewed ECs as empowering and essential, they also feared societal judgment from peers, healthcare providers, and the public [25]. Similarly, in Australia, Mooney-Somers et al. revealed that concerns about health risks, such as perceived impacts on fertility or birth defects, deterred many women from using ECs [26]. Alarmingly, 61% of women surveyed believed ECs could cause birth defects or miscarriage, while 39% were unsure about their safety if a woman was unknowingly pregnant [26]. These misconceptions highlight the critical need for accurate education and destigmatization to encourage appropriate use of ECs.

Misinformation and lack of knowledge among patients also create barriers to EC access. For instance, Mollen et al. found that while 63.7% of surveyed adolescents had heard of ECs, most lacked a clear understanding of their timing and use [27]. Another case involved a newborn presenting with isolated bilateral microtia, potentially linked to isotretinoin exposure [28]. The mother had completed a course of isotretinoin four weeks before conceiving and adhered to the recommended one-month post-treatment contraception protocol. Despite her compliance, exposure during early pregnancy resulted in significant congenital anomalies [28]. This case highlights the importance of extending contraceptive counseling to emphasize the residual risks associated with isotretinoin, even after discontinuation.

Concerns about side effects, cost, and privacy further discouraged access. Among non-sexually active participants, the fear of judgment from healthcare providers and peers was particularly prominent [27]. This lack of awareness is not confined to adolescents; a survey at Princeton University revealed widespread confusion about ECs among college students, with only 48% able to distinguish ECs from the abortifacient RU-486 and just 38% knowing the correct timing for their use [29]. Addressing these knowledge gaps is crucial for ensuring that individuals understand ECs as a safe and effective tool for preventing unintended pregnancies.

Provider knowledge and attitudes further compound access challenges. A survey of physicians, physician assistants, and nurse practitioners revealed that 29% of respondents were unaware of the World Health Organization's recommendation to offer ECs up to 120 hours after unprotected intercourse [30]. This knowledge gap among healthcare providers underscores the importance of education and training to ensure consistent, evidence-based counseling. Positive interactions with healthcare providers have been shown to increase willingness to use ECs, as demonstrated by Berglas et al., who found that supportive and informative counseling was associated with improved attitudes toward EC use among young women [31]. Without such guidance, patients are often left navigating these decisions alone, further limiting access.

In dermatological settings, specific barriers arise from the perception that dermatologists are primarily focused on skin health rather than broader reproductive health concerns. Patients may not view their dermatologist as a resource for family planning or contraceptive advice, particularly when the focus of their visit is acne management [32]. This perception can discourage patients from bringing up concerns about contraception or EC during dermatology appointments. Dermatologists themselves may lack the training or resources needed to address these issues comprehensively. For example, while oral EC options like LNG and UPA can be prescribed by dermatologists, procedural options like the copper IUD require referrals to other providers [32]. Additionally, factors such as patient weight, cost, and geographical access to pharmacies or clinics further complicate timely access to ECs [32].

Many dermatologists feel unprepared to counsel patients on emergency contraception. Swink et al. found that while 75.3% of dermatology residents were comfortable discussing combined oral contraceptives (COCs) as part of iPLEDGE requirements, only 33.5% felt confident counseling patients about ECs when initiating isotretinoin therapy [33]. This gap in training highlights an urgent need for improved education within dermatology to ensure that patients have access to comprehensive reproductive health guidance during their isotretinoin treatment. Overcoming barriers to EC access requires a multifaceted approach. Education and training for healthcare providers, including dermatologists, are essential to ensuring that patients receive accurate, nonjudgmental information about their options. Destigmatizing EC use through patient-centered counseling can empower individuals to make informed decisions about their reproductive health without fear of judgment. Additionally, integrating EC discussions into dermatology practice, particularly during isotretinoin consultations, represents an important step toward bridging gaps in care. By addressing these barriers, dermatologists can play a vital role in reducing the risks of unintended pregnancies and improving patient outcomes.

Integrating Emergency Contraceptive Prescriptions into Isotretinoin Therapy

Integrating emergency contraception into isotretinoin therapy is a practical and ethical approach to reducing unintended pregnancies and preventing isotretinoin-exposed teratogenic risks. EC serves as a critical safety net in cases of contraceptive failure or inconsistent use. Dermatologists should routinely discuss EC with patients at the initiation of isotretinoin therapy, ensuring that they are informed about the timing, effectiveness, and availability of different EC options. Proactively prescribing oral EC options, such as UPA or LNG, at the start of isotretinoin therapy ensures that patients have immediate access if needed.

Education plays a vital role in integrating EC into isotretinoin care. Dermatologists should emphasize the importance of timely EC use in cases of contraceptive failure or unprotected intercourse. They should also provide clear guidance on how different contraceptive methods vary in effectiveness and availability. Additionally, barriers to accessing EC, such as cost, stigma, and limited availability, must also be addressed during patient counseling. Some patients may face challenges obtaining EC due to geographic or financial constraints, particularly in rural or underserved areas. Dermatologists can mitigate these barriers by prescribing EC in advance, reducing delays and ensuring immediate access if needed. Creating an open, judgment-free environment for discussing contraception can also alleviate stigma and encourage patients to seek EC without hesitation. Normalizing these conversations within isotretinoin care fosters trust and strengthens the patient-provider relationship.

Collaboration with other healthcare providers, such as gynecologists and primary care physicians, can further enhance the integration of EC into isotretinoin therapy. Interdisciplinary care models enable dermatologists to refer patients for LARC placement or other specialized contraceptive needs while ensuring continuity of care. Research suggests that such collaborative approaches improve patient satisfaction and adherence to contraception protocols, reducing the risk of isotretinoin-exposed pregnancies [34]. For patients unable or unwilling to access these services, dermatologists should prioritize discussing readily accessible options like oral EC and provide resources to facilitate timely use.

Regular follow-up appointments provide an opportunity to reinforce the importance of pregnancy prevention measures and address any issues with current contraceptive methods [19]. Dermatologists should encourage patients to share concerns about their contraceptive plan and adjust recommendations as needed to ensure optimal adherence. Additionally, fostering open communication allows patients to feel comfortable seeking advice on emergency contraception, reducing the likelihood of misinformation or delayed action in critical situations. Integrating emergency contraception into isotretinoin therapy not only enhances pregnancy prevention efforts but also reflects a commitment to comprehensive, patient-centered care. By proactively addressing the risks of contraceptive failure and empowering patients with knowledge and resources, dermatologists can significantly reduce the incidence of unintended pregnancies and the devastating consequences of isotretinoin teratogenicity.

Future Directions

Future efforts should focus on integrating comprehensive reproductive health education into dermatology practice, particularly for patients prescribed isotretinoin. Enhanced training programs for dermatologists should emphasize counseling on ECs, ensuring providers feel confident addressing reproductive health concerns. Collaborative models of care, where dermatologists work closely with gynecologists or primary care providers, could expand access to LARCs and procedural options like the copper IUD. Additionally, revising protocols in programs like iPLEDGE to mandate more robust education on EC and its use as a critical safeguard against contraceptive failure is essential. Future research should evaluate the impact of integrating EC prescriptions into isotretinoin therapy on unintended pregnancy rates, particularly in underserved or high-risk populations. Leveraging telemedicine to enhance patient access to contraceptive counseling and follow-up care offers another promising avenue. By adopting these approaches, the field of dermatology can move toward more comprehensive, patient-centered care that addresses both dermatologic and reproductive health needs.

Conclusion

Integrating emergency contraceptives into isotretinoin therapy is a practical and ethical response to the persistent risk of teratogenic exposure from unintended pregnancies. By proactively addressing gaps in patient education, access, and contraceptive adherence, dermatologists can safeguard patient health and uphold their ethical responsibilities. Incorporating EC into routine care not only minimizes the devastating consequences of isotretinoin-exposed pregnancies but also fosters trust and empowers patients to make informed decisions about their reproductive health. This approach aligns with the principles of beneficence, nonmaleficence, and patient-centered care, ensuring dermatologic treatments like isotretinoin can be administered safely and effectively. Moving forward, the dermatology community must embrace these strategies to enhance outcomes and set a higher standard of comprehensive care.

Bibliography

1. Barbieri JS. Isotretinoin for Treatment of Acne. JAMA Dermatol. 2023;159(12):1403. doi:10.1001/jamadermatol.2023.2065
2. Sladden MJ, Harman KE. What Is the Chance of a Normal Pregnancy in a Woman Whose Fetus Has Been Exposed to Isotretinoin? Arch Dermatol. 2007;143(9):1187-1188. doi:10.1001/archderm.143.9.1187
3. Cyrulnik AA, Gewirtzman AJ, Paz KB, et al. iPLEDGE Weaknesses: Is It Time to Address the Flaws? 2016;15(1).
4. Owens KE, Jiang SW, Nicholas MW. Contraceptive counseling for iPLEDGE and its burden on dermatologists. Arch Dermatol Res. 2024;316(6):287. doi:10.1007/s00403-024-03070-5
5. Dreno B, Bagatin E, Blume-Peytavi U, Rocha M, Gollnick H. Female type of adult acne: Physiological and psychological considerations and management. JDDG J Dtsch Dermatol Ges. 2018;16(10):1185-1194. doi:10.1111/ddg.13664
6. Faúndes A, Brache V, Alvarez F. Emergency contraception—clinical and ethical aspects. Int J Gynecol Obstet. 2003;82(3):297-305. doi:10.1016/S0020-7292(03)00221-2
7. Gemzell-Danielsson K, Rabe T, Cheng L. Emergency Contraception. Gynecol Endocrinol. 2013;29(sup1):1-14. doi:10.3109/09513590.2013.774591
8. EMERGENCY CONTRACEPTION: A LAST CHANCE TO PREVENT UNINTENDED PREGNANCY. Accessed December 2, 2024. https://addletonacademicpublishers.com/contents-crlsj/253-volume-6-2-2014/2293-emergency-contraception-a-last-chance-to-prevent-unintended-pregnancy.
9. Mierzejewska A, Walędziak M, Merks P, Różańska-Walędziak A. Emergency contraception – A narrative review of literature. Eur J Obstet Gynecol Reprod Biol. 2024;299:188-192. doi:10.1016/j.ejogrb.2024.06.015
10. Barbieri JS, Roe AH, Mostaghimi A. Simplifying contraception requirements for iPLEDGE: A decision analysis. J Am Acad Dermatol. 2020;83(1):104-108. doi:10.1016/j.jaad.2020.02.022
11. Pile HD, Sadiq NM. Isotretinoin. In: StatPearls. StatPearls Publishing; 2024. Accessed December 2, 2024. http://www.ncbi.nlm.nih.gov/books/NBK525949/
12. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-973.e33. doi:10.1016/j.jaad.2015.12.037
13. Choi EJ, Kim N, Kwak HS, et al. The rates of major malformations after gestational exposure to isotretinoin: a systematic review and meta-analysis. Obstet Gynecol Sci. 2021;64(4):364-373. doi:10.5468/ogs.20373
14. Lammer EJ, Chen DT, Hoar RM, et al. Retinoic Acid Embryopathy. N Engl J Med. 1985;313(14):837-841. doi:10.1056/NEJM198510033131401
15. Dai WS, LaBraico JM, Stern RS. Epidemiology of isotretinoin exposure during pregnancy. J Am Acad Dermatol. 1992;26(4):599-606. doi:10.1016/0190-9622(92)70088-W
16. Andresen M. Accutane registry compulsory in US, but not Canada. CMAJ. 2006;174(12):1701-1701. doi:10.1503/cmaj.060531
17. Tkachenko E, Singer S, Sharma P, Barbieri J, Mostaghimi A. US Food and Drug Administration Reports of Pregnancy and Pregnancy-Related Adverse Events Associated with Isotretinoin. JAMA Dermatol. 2019;155(10):1175-1179. doi:10.1001/jamadermatol.2019.1388
18. The Psychological Impact of Isotretinoin Therapy on Acne Vulgaris Patients | Cureus. Accessed December 2, 2024. https://www.cureus.com/articles/213932-the-psychological-impact-of-isotretinoin-therapy-on-acne-vulgaris-patients#!/
19. Werner CA, Papic MJ, Ferris LK, Schwarz EB. Promoting Safe Use of Isotretinoin by Increasing Contraceptive Knowledge. JAMA Dermatol. 2015;151(4):389-393. doi:10.1001/jamadermatol.2014.4171
20. Werner CA, Papic MJ, Ferris LK, et al. Women's Experiences with Isotretinoin Risk Reduction Counseling. JAMA Dermatol. 2014;150(4):366-371. doi:10.1001/jamadermatol.2013.6862
21. Altman EM. Isotretinoin and Pregnancy Prevention: Do We Need to Take a Long, Hard Look at Ourselves? JAMA Dermatol. 2014;150(4):361-362. doi:10.1001/jamadermatol.2013.6973
22. Westley E, Glasier A. Emergency contraception: dispelling the myths and misperceptions. Bull World Health Organ. 2010;88(4):243. doi:10.2471/BLT.10.077446.

23. Choi JS, Koren G, Nulman I. Pregnancy and isotretinoin therapy. CMAJ Can Med Assoc J. 2013;185(5):411-413. doi:10.1503/cmaj.120729
24. Smiley CE, Butt M, Zaenglein AL. Emergency contraception in the iPLEDGE program: A cross-sectional survey of pediatric dermatology provider understanding and practice. Pediatr Dermatol. 2022;39(5):727-730. doi:10.1111/pde.15086
25. Kabunga A, Kigongo E, Acanga A, et al. Qualitative study on stigma as a barrier to emergency contraceptive pill use among university students in the Lango subregion, Uganda. BMJ Open. 2024;14(2):e079478. doi:10.1136/bmjopen-2023-079478.
26. Mooney-Somers J, Lau A, Bateson D, et al. <no title>. Published online February 1, 2019.
27. Mollen CJ, Miller MK, Hayes KL, Barg FK. Knowledge, Attitudes, and Beliefs About Emergency Contraception: A Survey of Female Adolescents Seeking Care in the Emergency Department. Pediatr Emerg Care. 2013;29(4):469. doi:10.1097/PEC.0b013e31828a3249.
28. Shirazi M, Abbariki E, Pirjani R, Akhavan S, Dastgerdy E. Congenital microtia in a neonate due to maternal isotretinoin exposure 1 month before pregnancy: Case Report. J Obstet Gynaecol Res. 2015;41(6):975-978. doi:10.1111/jog.12644
29. Harper CC, Ellertson CE. The emergency contraceptive pill: A survey of knowledge and attitudes among students at Princeton University. Am J Obstet Gynecol. 1995;173(5):1438-1445. doi:10.1016/0002-9378(95)90630-4
30. Dehlendorf C, Levy K, Ruskin R, Steinauer J. Health care providers' knowledge about contraceptive evidence: a barrier to quality family planning care? Contraception. 2010;81(4):292-298. doi:10.1016/j.contraception.2009.11.006
31. Berglas NF, Kaller S, Mays A, Biggs MA. The Role of Health Care Providers in Young Women's Attitudes about and Willingness to Use Emergency Contraceptive Pills. Womens Health Issues. 2021;31(3):286-293. doi:10.1016/j.whi.2020.12.010